Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas

被引:0
作者
Julieann C. Lee
Melike Pekmezci
Jonathan L. Lavezo
Hannes Vogel
Laurence Katznelson
Merav Fraenkel
Griffith Harsh
Mohanpal Dulai
Arie Perry
Tarik Tihan
机构
[1] University of California,Division of Neuropathology, Department of Pathology
[2] Stanford University School of Medicine,Department of Pathology
[3] Stanford University School of Medicine,Department of Neurosurgery
[4] Trillium Health Partners,undefined
来源
Endocrine Pathology | 2017年 / 28卷
关键词
Pit-1; SF-1; Null cell adenoma; Pituitary adenoma; Clinically non-functioning pituitary adenoma; Silent adenoma; Sparsely granulated somatotroph adenoma; Transcription factors;
D O I
暂无
中图分类号
学科分类号
摘要
Pit-1 immunostaining is not routinely used in the characterization of pituitary adenomas, and its utility in distinguishing adenomas dedicated towards the lactotroph, somatotroph, and thyrotroph lineage from null cell adenomas warrants further evaluation. Pituitary adenomas that were negative for expression of a basic panel of hormonal markers (ACTH, prolactin, and growth hormone) were further evaluated for TSH, SF-1, and Pit-1 expression using a tissue microarray. Among the 147 identified pituitary adenomas that were negative for ACTH, prolactin, growth hormone, and TSH, expression of SF-1 was present in 68 cases (46%). Of the remaining 72 cases with sufficient tissue for further analysis, four were Pit-1 positive (6% of the adenomas negative for ACTH, prolactin, growth hormone, TSH, and SF-1); the remaining 68 were potentially null cell adenomas. Two of the Pit-1-positive adenomas displayed a paranuclear CAM 5.2 staining pattern suggestive of a sparsely granulated somatotroph adenoma; however, only one case contained fibrous bodies within a majority of the adenoma cells. Our data suggests that Pit-1 can be utilized as a second tier immunostain in cases of clinically non-functioning adenomas that are immunonegative for ACTH, prolactin, growth hormone, TSH, and SF-1 in order to further segregate rare cases of Pit-1-positive adenomas from null cell adenomas. Pit-1 immunostaining can recognize rare cases of sparsely granulated somatotroph adenomas that appear immunonegative for growth hormone, as well as rare cases of other Pit-1-positive adenomas that are negative for Pit-1 lineage hormones. Overall, pituitary adenomas of the Pit-1 lineage that do not produce prolactin, growth hormone, or TSH are rare, with only four cases identified in the current study.
引用
收藏
页码:287 / 292
页数:5
相关论文
共 13 条
[1]  
Asa SL(2009)The pathogenesis of pituitary tumors Annual Review of Pathology 4 97-126
[2]  
Ezzat S(1993)Cell type-specific expression of the pituitary transcription activator Pit-1 in the human pituitary and pituitary adenomas J Clin Endocrinol Metab 77 1275-1280
[3]  
Asa SL(2015)Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavorial Characteristics Endocrine Pathology 26 63-70
[4]  
Balogun JA(2015)The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas Endocrine Pathology 26 349-355
[5]  
Nishioka H(2017)A specific antibody to detect transcription factor T-pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours Acta Neuropathol 134 675-677
[6]  
Sjostedt E(2013)A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas Neurosurgery 73 8-17
[7]  
Jahangiri A(2017)Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary Pituitary 20 84-92
[8]  
Syro LV(1993)Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology Neurosurgery 33 20-27
[9]  
Yamada S(2015)Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype Pituitary 18 326-334
[10]  
Cheng-Chia L(2017)Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A rational starting place for the immunohistochemical characterization of pituitary adenoma Archives of pathology and laboratory medicine 141 104-112